| Autor: |
Zalyalova ZA; Kazan State Medical University, Kazan, Russia.; Rebublican Center for Movement Disorders, Kazan, Russia.; Hospital for War Veterans, Kazan, Russia., Khasanova DM; Rebublican Center for Movement Disorders, Kazan, Russia.; Hospital for War Veterans, Kazan, Russia. |
| Jazyk: |
ruština |
| Zdroj: |
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2021; Vol. 121 (9), pp. 152-156. |
| DOI: |
10.17116/jnevro2021121091152 |
| Abstrakt: |
The article provides an overview of the data on the impact of Parkinson's disease on the risk of infection and the course of COVID-19, and also assesses the possible pathogenetic relationship between the SARS-CoV-2 virus, COVID-19 and PD. By penetrating the central nervous system, SARS-CoV-2 can cause not only neurological symptoms, but also exacerbate the course of an existing neurological disease. The impact of Parkinson's disease on the risk of infection and the course of COVID-19 is controversial. However, a number of authors support the opinion that PD is an anti-risk factor for the development of COVID-19, which is associated both with the pathogenesis of the disease and with the used antiparkinsonian drugs, in particular amantadines. There are no clear data indicating higher risk of infection and higher severity of COVID-19 in patients with PD. On the contrary, experimental and clinical data suggest a possible modifying role of α-synuclein and antiparkinsonian drugs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
